文献速递类风湿关节炎

生物制剂DMARD在类风湿关节炎中的药物留存:基线特征与疾病演变的作用

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

结果显示停药与DAS28不良演变关联最强(HR 1.34,95%CI 1.29–1.40),其次为基线DAS28值;医生总体评估变化是次强预测因子,提示停药决策更依赖医生而非患者的总体评估。

要点

  • DAS28不良演变与停药关联最强(HR 1.34,95%CI 1.29–1.40)
  • 医生总体评估变化对停药的预测强度高于患者总体评估
  • 停药决策更多基于医生整体判断而非患者报告结局

核心结论

  • bDMARD停药决策主要受DAS28及其随时间演变的影响,其次为医生总体评估的演变,提示决策更依赖医生的整体评估而非患者的整体评估。

研究设计与样本

  • 从七个欧洲RA注册库中纳入2009年起启动bDMARD治疗且有访视日期信息的RA患者,采用Cox回归模型分析基线评估与随访变化同停药的关系,并按注册库和启动日历年分层。

主要发现

  • 停药与DAS28不良演变的关联最强,风险比1.34(95%CI 1.29,1.40),其次为基线DAS28值。
  • 医生总体评估的变化是停药的下一个最强预测因子,其后为患者总体评估。

临床怎么用

  • 在评估是否停用bDMARD时,应关注DAS28的动态演变而非仅基线值,并重视医生总体评估的变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association of the evolution in physician-reported and patient-reported outcomes with decision to stop biological DMARDs (bDMARDs) in RA. The contribution of baseline characteristics is well established, but little is known about how the disease evolution influences the decision to discontinue therapy. METHODS: RA patients who initiated a bDMARD treatment from 2009 and with information on date of visit were pooled from seven European RA registers. Each outcome was divided into baseline assessments (capturing the inter-individual differences at drug initiation) and changes from baseline at subsequent visits (capturing the individual evolution). Cox regression models were used to examine their association with drug discontinuation, adjusting for baseline patient and co-therapy characteristics and stratifying by register and calendar year of drug initiation. RESULTS: A total of 25 077 patients initiated a bDMARDs (18 507 a TNF-inhibitor, 3863 tocilizumab and 2707 abatacept) contributing an amount of 46 456.8 patient-years. Overall, drug discontinuation was most strongly associated with a poor evolution of the DAS28, with a hazard ratio of 1.34 (95% CI 1.29, 1.40), followed by its baseline value. A change of Physician Global Assessment was the next strongest predictor of discontinuation, then the Patient Global Assessment. CONCLUSIONS: The decision to discontinue treatments appears to be mostly influenced by DAS28 and particularly its evolution over time, followed by Physician Global Assessment evolution, suggesting that the decision to stop bDMARDs relies more on the physician's than on the patient's global assessment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lauper K, Mongin D, Alpizar-Rodriguez D, et al. Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology (Oxford). 2019. PMID: 31209481. doi:10.1093/rheumatology/kez221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。